Alice C Wei1,2, Fang-Shu Ou3, Qian Shi3, Xiomara Carrero3, Eileen M O'Reilly4, Jeffrey Meyerhardt5, Robert A Wolff6, Hedy L Kindler7, Douglas B Evans8, Vikram Deshpande9, Joseph Misdraji9, Eric Tamm6, Dushyant Sahani9, Malcolm Moore10, Elliot Newman11, Nipun Merchant12, Jordan Berlin13, Laura W Goff13, Peter Pisters6, Mitchell C Posner7. 1. University Health Network-Princess Margaret Hospital, Toronto, ON, Canada. weia@mskcc.org. 2. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weia@mskcc.org. 3. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA. 4. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Dana-Farber/Partners Cancer Care, Boston, MA, USA. 6. MD Anderson Cancer Center, Houston, TX, USA. 7. University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 8. Medical College of Wisconsin, Milwaukee, WI, USA. 9. Massachusetts General Hospital Cancer Center, Boston, MA, USA. 10. University Health Network-Princess Margaret Hospital, Toronto, ON, Canada. 11. New York University Langone Medical Center, New York, NY, USA. 12. University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, FL, USA. 13. Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
BACKGROUND: There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC. METHODS: A multicenter, cooperative group, single-arm, phase II trial was conducted between April 2009 and November 2013 (ACOSOG Z5041). Patients with biopsy-confirmed PDAC in the pancreatic head without evidence of involvement of major mesenteric vessels (resectable) were eligible. Patients (n = 123) received an 8-week cycle of G+E before and after surgery. The primary endpoint was 2-year overall survival (OS), and secondary endpoints included toxicity, response, resection rate, and time to progression. Resectability was assessed retrospectively by central review. The study closed early due to slow accrual, and no formal hypothesis testing was performed. RESULTS: Overall, 114 patients were eligible, consented, and initiated protocol treatment. By central radiologic review, 97 (85%) of the 114 patients met the protocol-defined resectability criteria. Grade 3+ toxicity was reported in 60% and 79% of patients during the neoadjuvant phase and overall, respectively. Twenty-two of 114 (19%) patients did not proceed to surgery; 83 patients (73%) were successfully resected. R0 and R1 margins were obtained in 67 (81%) and 16 (19%) resected patients, respectively, and 54 patients completed postoperative G+E (65%). The 2-year OS rate for the entire cohort (n = 114) was 40% (95% confidence interval [CI] 31-50), with a median OS of 21.3 months (95% CI 17.2-25.9). The 2-year OS rate for resected patients (n = 83) was 52% (95% CI 41-63), with a median OS of 25.4 months (95% CI 21.8-29.6). CONCLUSIONS: For resectable PDAC, perioperative G+E is feasible. Further evaluation of neoadjuvant strategies in resectable PDAC is warranted with more active systemic regimens.
BACKGROUND: There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC. METHODS: A multicenter, cooperative group, single-arm, phase II trial was conducted between April 2009 and November 2013 (ACOSOG Z5041). Patients with biopsy-confirmed PDAC in the pancreatic head without evidence of involvement of major mesenteric vessels (resectable) were eligible. Patients (n = 123) received an 8-week cycle of G+E before and after surgery. The primary endpoint was 2-year overall survival (OS), and secondary endpoints included toxicity, response, resection rate, and time to progression. Resectability was assessed retrospectively by central review. The study closed early due to slow accrual, and no formal hypothesis testing was performed. RESULTS: Overall, 114 patients were eligible, consented, and initiated protocol treatment. By central radiologic review, 97 (85%) of the 114 patients met the protocol-defined resectability criteria. Grade 3+ toxicity was reported in 60% and 79% of patients during the neoadjuvant phase and overall, respectively. Twenty-two of 114 (19%) patients did not proceed to surgery; 83 patients (73%) were successfully resected. R0 and R1 margins were obtained in 67 (81%) and 16 (19%) resected patients, respectively, and 54 patients completed postoperative G+E (65%). The 2-year OS rate for the entire cohort (n = 114) was 40% (95% confidence interval [CI] 31-50), with a median OS of 21.3 months (95% CI 17.2-25.9). The 2-year OS rate for resected patients (n = 83) was 52% (95% CI 41-63), with a median OS of 25.4 months (95% CI 21.8-29.6). CONCLUSIONS: For resectable PDAC, perioperative G+E is feasible. Further evaluation of neoadjuvant strategies in resectable PDAC is warranted with more active systemic regimens.
Authors: Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad Journal: Ann Surg Oncol Date: 2013-02-23 Impact factor: 5.344
Authors: Eileen M OʼReilly; Anna Perelshteyn; William R Jarnagin; Mark Schattner; Hans Gerdes; Marinela Capanu; Laura H Tang; Joseph LaValle; Corinne Winston; Ronald P DeMatteo; Michael DʼAngelica; Robert C Kurtz; Ghassan K Abou-Alfa; David S Klimstra; Maeve A Lowery; Murray F Brennan; Daniel G Coit; Diane L Reidy; T Peter Kingham; Peter J Allen Journal: Ann Surg Date: 2014-07 Impact factor: 12.969
Authors: Marlo Blazer; Christina Wu; Richard M Goldberg; Gary Phillips; Carl Schmidt; Peter Muscarella; Evan Wuthrick; Terrence M Williams; Joshua Reardon; E Christopher Ellison; Mark Bloomston; Tanios Bekaii-Saab Journal: Ann Surg Oncol Date: 2014-10-31 Impact factor: 5.344
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler Journal: JAMA Date: 2010-09-08 Impact factor: 56.272
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook Journal: JAMA Surg Date: 2016-08-17 Impact factor: 14.766
Authors: Matthew H G Katz; Fang-Shu Ou; Joseph M Herman; Syed A Ahmad; Brian Wolpin; Robert Marsh; Spencer Behr; Qian Shi; Michael Chuong; Lawrence H Schwartz; Wendy Frankel; Eric Collisson; Eugene J Koay; JoLeen M Hubbard; James L Leenstra; Jeffrey Meyerhardt; Eileen O'Reilly Journal: BMC Cancer Date: 2017-07-27 Impact factor: 4.430
Authors: Rebecca Y Kim; Kathleen K Christians; Mohammed Aldakkak; Callisia N Clarke; Ben George; Mandana Kamgar; Abdul H Khan; Naveen Kulkarni; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: Ann Surg Oncol Date: 2020-09-30 Impact factor: 5.344